Lazaris A C, Davaris P, Nakopoulou L, Theodoropoulos G E, Koullias G, Golematis B C
Department of Pathology, Medical School, Athens University, Greece.
Dis Colon Rectum. 1994 Nov;37(11):1083-9. doi: 10.1007/BF02049808.
Proliferating cell nuclear antigen immunohistochemical expression and flow cytometry techniques were used in this study to estimate the proliferation tendency and biologic aggressiveness in benign and malignant epithelial tumors of the colon and rectum.
Thirty-five adenomas and 60 adenocarcinomas were studied immunohistochemically concerning proliferating cell nuclear antigen positivity in tumor cell nuclei. In addition, flow cytometry techniques were used to estimate the DNA content and percentage of tumor cells in the S-phase.
The mean proliferating cell nuclear antigen score for adenomas was 38 percent compared with a mean score of 50.4 percent for adenocarcinomas that were studied (P < 0.05). In dysplastic areas of malignantly transformed adenomas (n = 5), the highest proliferating cell nuclear antigen score (80 percent) was focally observed. Taking flow cytometry parameters into account, we found out that proliferating cell nuclear antigen can be used as an indirect indicator of the number of cells in the S-phase (SPF) but not as an independent prognostic factor. Statistical significance was found between Type III (aneuploid carcinomas) and increased proliferating cell nuclear antigen expression (proliferating cell nuclear antigen score > or = 60 percent). Furthermore, aneuploidy was especially found on cancer located on the left colon (44 percent vs. 14 percent of right colon neoplasms). Considering DNA ploidy of the above neoplasms, the aneuploid adenocarcinomas had a tendency for poorer prognosis especially if they were related to Dukes Stage C female patients.
The comparative assessment of the above parameters might be of considerable importance in the study of the proliferation activity of any form of colorectal neoplasia.
本研究采用增殖细胞核抗原免疫组化表达和流式细胞术技术，评估结肠和直肠良恶性上皮肿瘤的增殖倾向和生物学侵袭性。
对35例腺瘤和60例腺癌进行免疫组化研究，观察肿瘤细胞核中增殖细胞核抗原的阳性情况。此外，采用流式细胞术技术评估DNA含量和肿瘤细胞S期百分比。
腺瘤的增殖细胞核抗原平均评分为38%，而所研究的腺癌平均评分为50.4%（P<0.05）。在恶性转化腺瘤的发育异常区域（n=5），局部观察到最高的增殖细胞核抗原评分（80%）。考虑到流式细胞术参数，我们发现增殖细胞核抗原可作为S期细胞数量（SPF）的间接指标，但不能作为独立的预后因素。在III型（非整倍体癌）和增殖细胞核抗原表达增加（增殖细胞核抗原评分≥60%）之间发现了统计学意义。此外，非整倍体尤其见于左半结肠癌（44% vs. 右半结肠肿瘤的14%）。考虑到上述肿瘤的DNA倍体情况，非整倍体腺癌预后较差，尤其是与Dukes C期女性患者相关时。
对上述参数的比较评估在研究任何形式的结直肠肿瘤增殖活性方面可能具有相当重要的意义。
